Therapy Advancements and Biomarker Identifications Leading to Improved Ability to Predict and Enhance Responses To Immunotherapeutic Agents In Non–Small Cell Lung Cancer (NSCLC)

Therapy Advancements and Biomarker Identifications Leading to Improved Ability to Predict and Enhance Responses To Immunotherapeutic Agents In Non–Small Cell Lung Cancer (NSCLC)

Targeted therapy advancements and the identification of emerging biomarkers of response to treatment have led to an improved ability to predict and enhance responses to immunotherapeutic agents in non–small cell lung cancer (NSCLC). Available agents that have...
Institut Jules Bordet Retrospective Study Reveals Findings of Autoimmune Disorders and Immune Checkpoint Inhibitors with RCC and UC

Institut Jules Bordet Retrospective Study Reveals Findings of Autoimmune Disorders and Immune Checkpoint Inhibitors with RCC and UC

There is little available data on the safety and clinical mechanism of immune checkpoint inhibitors (CPI) due to the fact that patients with renal cell carcinoma (RCC) or urothelial carcinoma (UC) struggling with significant autoimmune disorders (AD) are typically...

Pin It on Pinterest